China's Tasly Pharma said to mull listing biotech unit in $1b Hong Kong IPO

Photo: Tasly website

China’s Tasly Pharmaceutical Group is planning to list its biopharma unit in Hong Kong to raise about $1 billion, in what is likely to be the largest biotech float in the city this year, people with knowledge of the matter said.

The plan comes as Hong Kong Exchanges and Clearing, the city’s exchange operator, is proposing changes to its listing rules to woo early-stage drug developers.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter